Shannon Bates Shannon Bates, MDCM, MSc, FRCPC
Read bio
Mary Cushman.png Mary Cushman, MD, MSc
Read bio
Agnes Lee Agnes Y. Y. Lee, MD, MSc, FRCPC
Read bio


Dr. Marc Rodger Marc Rodger, MD, FRCPC, MSc
Read bio
Dr. Suresh Vedantham Suresh Vedantham, MD
Read bio
Dr. Phil Wells Phil Wells, MD, FRCP(C), MSc
Read bio



Shannon Bates, MDCM, MSc, FRCPC
Dr. Bates’ clinical and academic interests are in venous thromboembolism, with a focus on thrombosis issues in women. Dr. Bates has published over 120 peer-review manuscripts and given over 130 invited presentations. She was lead author for the chapter examining the use of antithrombotic agents during pregnancy in the 7th, 8th and 9th editions of the American College of Chest Physicians (ACCP) Evidence-Based Clinical-Practice Guidelines for Antithrombotic and Thrombolytic Therapy and for a new chapter examining the diagnosis of deep vein thrombosis for the 9th edition of those guidelines. She was the Chair of the 2018 American Society of Hematology Guideline Panel on VTE in the context of pregnancy and a member of the panel on VTE diagnosis. On January 1, 2014, Dr. Bates was named McMaster University’s Eli Lilly Canada/May Cohen Chair in Women’s Health. She is the Vice Chair of the Royal College of Physicians and Surgeons of Canada Area of Focused Competence Committee in Adult Thrombosis Medicine and Co-Editor in Chief of Thrombosis Research.


Mary Cushman, MD, MSc

Mary Cushman, MD, MSc is Professor of Medicine and Pathology & Laboratory Medicine at the Larner College of Medicine at the University of Vermont (UVM). She is Vice-Chair for Emerging Researchers of the Department of Medicine, Director of the Thrombosis and Hemostasis Program in the Hematology-Oncology Division, Board Director of the Cardiovascular Research Institute, and Co-Director of the Vermont Center for Cardiovascular and Brain Health, an NIH-funded Center of Biomedical Research Excellence (COBRE).

She completed MD, residency and fellowship at UVM and a Master of Science in Epidemiology at Harvard. 

With continuous NIH funding for >25 years, she studies causative factors for heart disease, stroke, cognitive impairment and venous thrombosis using molecular epidemiology approaches. More recently she is engaged in treatment trials in COVID-19. She is the inaugural Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, a journal of the International Society on Thrombosis and Haemostasis. Her h-index is 137; she has authored >650 peer-reviewed original articles, 22 guidelines and society statements, and >30 reviews or commentaries.

Among many accolades, Cushman received the American Heart Association 2018 Population Research Prize recognizing research achievement, and their 2020 Award of Meritorious Achievement, for her impact on promoting the careers of early career professionals and women in science and medicine. She is an elected member of the Association of American Physicians.


Agnes Y. Y. Lee, MD, MSc, FRCPC
Dr. Agnes Y. Y. Lee is the Medical Director of the Thrombosis Program and Professor of Medicine at the University of British Columbia, Vancouver, BC, Canada.

Dr. Lee’s primary clinical research interest is in cancer-associated thrombosis and venous thromboembolism in other high-risk populations. Dr. Lee earned her Doctorate of Medicine and completed her residency in Internal Medicine at the University of British Columbia. She obtained her training in Hematology and Thrombosis and earned her Masters of Science in Health Research Methodology at McMaster University.


Marc Rodger, MD
Dr. Marc Rodger is the Chair of the McGill University Department of Medicine, Physician-in-Chief, McGill University Health Center and the Harry Webster Thorp Professor of Medicine.
Dr. Rodger’s teaching, clinical care and research focuses on venous thrombosis. His venous thrombosis research agenda focuses on two areas: Duration of Anticoagulation and Pregnancy. He has published over 240 research articles including multiple first/senior author papers in the New England Journal of Medicine and Lancet. His work has been cited over 19,000 times. Over his career, he has secured over 43 million in peer reviewed research funding (over 21 million as Principle Investigator). Dr. Rodger was Editor in Chief of Thrombosis Research, a major sub-speciality journal in his area of research.

Dr. Rodger co-founded, co-directs and obtained CIHR funding for CanVECTOR (Canadian Venous Thrombosis Clinical Trials and Outcomes Research) Network (www.CanVECTOR.ca). This network includes over 160 members in over 25 research sites across Canada. Dr. Rodger also founded and is current Chair of INVENT (International Network of Venous Thrombosis Clinical Research Networks) (www.INVENT-VTE.com). INVENT includes 10 national research networks with over 450 investigators in over 150 research sites throughout the world.


Suresh Vedantham, MD
Dr. Vedantham, Professor of Radiology & Surgery at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis, is an experienced Interventional Radiologist who specializes in the delivery and clinical investigation of image-guided therapies for venous thromboembolism (VTE). He has a robust clinical practice in which he sees patients with complex vascular/thrombotic disorders who are referred to him locally, nationally, and internationally for treatment that often includes innovative, image-guided, procedures. Dr. Vedantham is a leading clinical scientist in the field of thrombosis. As the national Principal Investigator of the completed 56-center ATTRACT Trial and the ongoing 35-Center C-TRACT Trial (both NHLBI sponsored) and their Clinical Coordinating Centers, and as past-Director of the Administrative Core of Washington University’s NHLBI-sponsored Center for Translational Therapies in Thrombosis, Dr. Vedantham has outstanding organizational skills and significant experience in overcoming scientific, regulatory, accrual, and environmental barriers to multicenter clinical trials. Dr. Vedantham is recognized as an outstanding leader of collaborative multidisciplinary endeavors, having held positions on the executive boards of professional organizations and public-private coalitions including the American Venous Forum, American College of Phlebology, American Board of Phlebology, Vascular Disease Foundation, and Venous Disease Coalition. Dr. Vedantham recently served as President of the Society of Interventional Radiology. In 2008, Dr. Vedantham was publicly thanked by the U.S. Surgeon General for his efforts in bringing together the community of providers and patients around deep vein thrombosis (DVT). In 2020, Dr. Vedantham served on the interventional sub-committee of the NHLBI State of Science Meeting on Pulmonary Embolism.

Dr. Vedantham serves as Assistant Dean for Clinical Research, Medical Director of the Center for Clinical Studies, and Adviser to the Vice-Chancellor for Research at Washington University in St. Louis. He also served as Co-Chair of the NHLBI’s Work Group on Designing Clinical Trials for Uncommon Disorders and Therapeutics. Dr. Vedantham leads the Network Capacity Function for Washington University’s CTSA Program), including its successful implementation of a fast-track team to expedite clinical trial start-up, and its creation of an internal Trial Coordination Acceleration Recruitment Enhancement (Trial-CARE) Multicenter Clinical Trial Support Center.


Phil Wells, MD, FRCP(C), MSc
Professor, Department of Medecine, The University of Ottawa, Faculty of Medicine and The Ottawa Hospital
Distinguished Research Chair in Thrombosis
University of Ottawa Research Chair
Senior Scientist, Ottawa Hospital Research Institute

Dr Wells was the Chief/Chair of the Department of Medicine at The Ottawa Hospital and the University of Ottawa until June 2021 and now is a Distinguished Research Chair in the Department of Medicine at the University of Ottawa. He received his medical school education and specialty training in Internal Medicine at the University of Ottawa. He then studied Hematology and completed a Masters in Clinical Epidemiology at McMaster University, concentrating on the special problems of venous thrombosis (blood clots in the veins). He came on Faculty at UO in 1994 and established the Thrombosis Treatment and Assessment Unit at The Ottawa Hospital, now the largest thrombosis clinical practice and clinical research unit in the world. He is best known for pioneering the concept of clinical prediction rules to assist in the diagnosis of patients with suspected deep vein thrombosis and/or pulmonary embolism. For each of these diseases he embodied these prediction rules in valuable algorithms now known as the “Wells Model for DVT” and the “Wells Model for PE”. They are currently used world-wide in the diagnostic process for these illnesses and are incorporated into many National and Organizational guidelines. His current interests are Cancer Associated Thrombosis and in promoting the use of AI to improve or develop clinical predictive analytics.

Dr. Wells has received over $35 million in peer reviewed research funding and has over 400 publications in a wide array of prestigious journals such as the New England Journal of Medicine, JAMA, Circulation, Blood, Nature Genetics and Lancet. His work has been acknowledged through a Canada Research Chair (2001 to 2011), The Ottawa Hospital J. David Grimes Career Achievement Award in 2012, a University of Ottawa Lifetime Achievement Award in 2014, a University of Ottawa Research Chair in 2019 and a Faculty of Medicine Distinguished Research Chair in 2021.